Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01517945 · ClinicalTrials.gov registry record

Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study

A clinical trial of Breast Cancer and Rare Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
252
Enrollment target
1
Study location

NCT01517945 is a study of Breast Cancer and Rare Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 252 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01517945, a study of Breast Cancer and Rare Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
252 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test, customize, and personalize a mobile app-based intervention program in order to help rare and breast cancer survivors cope with fears of cancer recurrence.

Interventions

  • BEHAVIORAL AIM materials and assessments

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 252 participants
Start Date 2012-01
Est. Completion 2027-01

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT01517945

The ClinicalTrials.gov registry entry for NCT01517945 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AIM materials and assessments is the first listed.

NCT01517945 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01517945 about?

NCT01517945 is a clinical study titled "Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study". The purpose of this study is to test, customize, and personalize a mobile app-based intervention program in order to help rare and breast cancer survivors cope with fears of cancer recurrence.

What is the current status of trial NCT01517945?

This trial is currently active not recruiting. The enrollment target is 252 participants. The study started on 2012-01. Estimated completion is 2027-01.

What conditions does trial NCT01517945 study?

This clinical trial studies the following conditions: Breast Cancer, Rare Cancer.

What interventions are being tested in trial NCT01517945?

The interventions under investigation include: AIM materials and assessments (BEHAVIORAL).

Who is sponsoring clinical trial NCT01517945?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01517945 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.